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Abstract
Background: Pituitary cysts have been speculated to cause 
endocrinopathies. We sought to describe the prevalence and 
volumetry of pituitary cysts in patients with growth hormone 
deficiency (GHD) and idiopathic short stature (ISS).
Methods: Six hundred and eighteen children evaluated 
for growth failure at the Division of Pediatric Endocrinol-
ogy at New York Medical College between the years 2002 
and 2012, who underwent GH stimulation testing and had 
a brain magnetic resonance imaging (MRI) prior to initi-
ating GH treatment were randomly selected to be a part 
of this study. High resolution MRI was used to evaluate 
the pituitary gland for size and the presence of a cyst. 
Cyst prevalence, cyst volume and percentage of the gland 
occupied by the cyst (POGO) were documented.
Results: Fifty-six patients had a cyst, giving an overall 
prevalence of 9.1%. The prevalence of cysts in GHD 
patients compared to ISS patients was not significant 
(13.5% vs. 5.7%, p = 0.46). Mean cyst volume was greater 
in GHD patients than ISS patients (62.0 mm3 vs. 29.4 mm3, 
p = 0.01). POGO for GHD patients was significantly 
greater (p = 0.003) than for ISS patients (15.3% ± 12.8 vs. 
7.1% ± 8.0). Observers were blinded to patient groups.
Conclusions: GHD patients had a significantly greater 
volume and POGO compared to ISS patients. This raises 
the question of whether cysts are implicated in the 
pathology of growth failure.
Keywords: endocrinopathy; growth disorders; growth 
hormone deficiency; growth hormone stimulation test; 
hypopituitarism; magnetic resonance imaging; pituitary; 
pituitary disease; pituitary volume; short stature.
Introduction
High resolution magnetic resonance imaging (MRI) evalu-
ation of the pituitary gland has become essential in the 
assessment of the growth hormone deficient (GHD) child 
[1–3]. This new MRI technique allows for greater detailed 
observations to be made [4–6]. As a result, the endocri-
nologist may discover new and more frequent radio-
graphic findings, including pituitary cysts [7–9]. We have 
previously shown a 14.6% prevalence of pituitary cysts in 
pediatric patients [Abstract: Incidence and volumetry of 
pituitary cysts in normal children]. One could easily spec-
ulate that compression of the pituitary by cysts may cause 
dysfunction in secretion in the somatotrophs and other 
cells of the pituitary gland [10–12]. This study sought to 
compare the prevalence and volumetry of pituitary cysts 
between GHD and idiopathic short stature (ISS) children.
Subjects and methods
Subjects
All children evaluated for growth failure seen in the Division of Pedi-
atric Endocrinology at New York Medical College from 2002 to 2012, 
who had a bone age demonstrating open growth plates and had high 
resolution MRI and GH stimulation testing performed were consid-
ered for this study. Growth failure was defined as having a height less 
than 2.0 standard deviations below the mean on the Centers for Dis-
ease Control (CDC) growth curve, a subnormal growth velocity for at 
least 6 months and/or a predicted adult height greater than 5.08 cm 
discrepant from the mid-parental height. A GH peak of less than or 
equal to 10 ng/mL on stimulation was defined as GHD. Those with 
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levels greater than 10 ng/mL were classified as ISS. The secretagogues 
utilized during the GH stimulation test were clonidine and levodopa. 
Clonidine was administered at 0.004  mg/kg by mouth with 0.05 
or 0.1 mg tablet, and 7–10 mg/kg of levodopa was administered by 
mouth with 125, 250, 375, or 500 mg tablet. GH levels were measured 
at our in-house endocrine laboratory via the chemiluminescent assay 
technique [13]. Patients were separated into two groups. Group 1 was 
considered the prepubertal patients, as defined by an age ≤11 years. 
Group 2 was considered the pubertal patients, as defined by an age 
>11  years. Patients with Turner syndrome, SHOX gene mutation, 
Cushing’s syndrome, hypothyroidism, other anterior pituitary hor-
mone deficiencies and malnutrition were excluded from this study. 
As this was a retrospective study of pre-existing data accumulated in 
our division, it was not necessary to obtain informed consent.
Magnetic resonance imaging (MRI)
MRI scans were taken on a Philips 1.5 Tesla MRI system (Koninklijke 
Philips N. V. Amsterdam, The Netherlands). Post-gadolinium con-
trast brain MRIs with special attention to the pituitary gland were 
reviewed for the presence of pituitary cysts. Image slices of 1–2 mm 
thickness were used for both sagittal and coronal images. Fluid-filled 
lesions were defined as cysts and were only distinguishable by size, 
and an identified mass was considered an adenoma and excluded 
from the study. Patients were referred for dynamic scanning when 
a lesion could not be classified otherwise. Pituitary and cyst length 
and height were measured using mid-sagittal images, while width 
was obtained using coronal images at the level of the pituitary stalk 
entrance into the gland. Pituitary volumes and cyst volumes were 
calculated using the ellipsoidal formula (l × w × h)/2. Percentage of 
the gland occupied by the cyst (POGO) was calculated with the for-
mula (cyst volume/pituitary volume) × 100. A cyst with a POGO less 
than 15% was defined as a small cyst, and a POGO greater than 15% 
was defined as a large cyst.
Statistical analysis
All statistical analyses were performed using IBM SPSS software 
(IBM Corp. Armonk, NY, USA). Continuous variables were com-
pared using the two-tailed Student’s t-test and were presented as 
the mean ± standard deviation. Categorical variables were compared 
using the chi-squared (χ2) test. A p-value <0.05 was considered sta-
tistically significant.
Ethical approval
The research related to human use has complied with all the rele-
vant national regulations, institutional policies and is in accordance 
with the tenets of the Helsinki Declaration. The Institutional Review 
Board of New York Medical College approved this cross-sectional 
 retrospective study.
Results
Table 1 depicts the prevalence of cysts stratified by the 
demographics of sex and age groups. Table 2 compares 
cyst volume and POGO, separated by diagnosis and age 
groups. Table 3 compares cyst volume and POGO, strati-
fied by sex and diagnosis. Table 4 displays the prevalence 
of large and small cysts by diagnosis.
Six hundred and eighteen patients met the criteria for 
inclusion in the study. Of these patients, 393  were male 
(64%) and 225 were female (36%). Two hundred and sixty-
six patients had GHD (43%), of which 181 were male (68%) 








Total  Male  Female  ≤11  >11 Total  Male  Female Total  Male  Female
n   618  393  225  233  385  266  181  85  352  212  140
# with cyst   56  39  17  23  33  36  27  9  20  12  8
Prevalence, %  9.1  9.9  7.5  9.87  8.57  13.5  14.9  10.6  5.7  5.7  5.7
Mean age   11.5  11.9  10.7  7.6  13.7  11.3  11.8  10.3  11.6  11.9  11.0
(SD age)   (3.4)  (3.5)  (3.2)  (2.9)  (2.0)  (3.4)  (3.5)  (3.2)  (3.4)  (3.5)  (3.1)
SD, standard deviation; GHD, growth hormone deficiency; ISS; idiopathic short stature.
Table 2: Cyst volume and POGO, separated by diagnosis and age group.
Cyst patients GHD ISS ≤11 >11
n 56 36 20 23 33
Mean cyst volume (SD) 51.1 (±58.9) 62.0 (±67.2) 29.4 (±38.4) 39.8 (±31.1) 58.7 (±71.3)
p-Value 0.01 0.19
Mean POGO (SD) 11.7% (±11.3) 15.3% (±12.8) 7.1% (±8.0) 13.1% (±12.6) 10.8% (±10.4)
p-Value 0.003 0.46
SD, standard deviation; POGO, percentage of the gland occupied by the cyst; GHD, growth hormone deficiency; ISS; idiopathic short stature.
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and 85  were female (32%). Three hundred and fifty-two 
had ISS (57%), of which 212 were male (60%) and 140 were 
female (40%).
Prevalence
Of the 618 patients studied, 56 had cysts, resulting in an 
overall prevalence of 9.1% (Table 1). GHD patients were 
found to have a prevalence of 13.5% compared to 5.7% 
for ISS patients (p = 0.46). This difference was not signifi-
cant. The prevalence between males and females of the 
entire cohort was not significant (9.9% and 7.5%, p = 0.79). 
When analyzed by age, 9.87% of prepubertal patients 
(group 1) showed pituitary cysts, while 8.57% of pubertal 
patients (group 2) demonstrated a cyst (p = 0.59, Table 1). 
The difference in prevalence between age groups was not 
significant.
Cyst volume
Cyst analysis showed a significant difference between cyst 
volume in GHD patients (mean 62.0  mm3 ± 67.2, median 
48.9) vs. ISS patients (mean 29.4  mm3 ± 38.4, median 
16.5) (p = 0.01). For males, the difference in cyst volume 
between GHD patients (mean 68.9  mm3 ± 74.9, median 
53.7) and ISS patients (mean 29.5 mm3 ± 46.7, median 14.5) 
was significant (p = 0.03). Cyst volume was greater in GHD 
females (mean 41.3 mm3 ± 29.6, median 34.5) than in ISS 
females (mean 29.2 mm3 ± 24.1, median 19.9), but this dif-
ference was not significant (p = 0.27). The group 2 patients 
had a larger cyst volume (58.67 mm3 ± 71.29 mm3) than the 
group 1 patients (39.76 mm3 ± 31.08 mm3). This difference 
was not significant (p = 0.19, Table 2).
POGO
The mean POGO of the cyst for GHD patients was 
15.3% ± 12.8 (median 13.5) and for ISS it was 7.1% ± 8.0 
(median 4.8). The difference between these two groups 
was statistically significant (p = 0.003). For males, the 
difference in POGO between the GHD (mean 16.4% ± 14.3, 
median 13.5) and ISS (mean 6.7% ± 9.0, median 4.1) groups 
was significant (p = 0.009). For females, the difference in 
POGO between the GHD (mean 11.8% ± 5.6, median 10.9) 
and ISS (mean 7.8% ± 6.6, median 5.4) groups was not 
significant (p = 0.16). Mean POGO in group 1 patients was 
13.08% ± 12.6 and mean POGO in group 2 patients was 
10.77% ± 10.4. This difference was not significant (p = 0.46, 
Tables 2 and 3).
In patients who had a pituitary cyst, 66.1% had a 
small cyst. For GHD and ISS patients with a cyst, small 
cysts were found in 55.6% and 85%, respectively. This 
difference was significant (p = 0.04). Large cysts were 
found in 33.9% of all patients with a cyst. For GHD and 
ISS patients with a cyst, large cysts were found in 44.4% 
and 15%, respectively. There was a significant difference 
between the percentage of GHD patients and ISS patients 
with large cysts (p = 0.04, Table 4).
Discussion
To the best of our knowledge, the data presented here is the 
first study to assess cyst prevalence and volumetry in chil-
dren with GHD and ISS. Pituitary cysts have been speculated 
to cause a variety of clinical findings, including anterior 
pituitary dysfunction, visual field defects, and headaches 
[11, 14–23]. This pathology may be caused by cyst com-
pression of the adenohypophysis [10–12]. Because soma-
totrophs are the most abundant cell type of the pituitary 
Table 3: Volumetry of pituitary cysts by sex and diagnosis.
GHD male ISS male GHD female ISS female
n 27 12 9 8
Mean cyst volume (SD) 68.9 (±74.9) 29.5 (±46.7) 41.3 (±29.6) 29.2 (±24.1)
p-Value 0.03 0.27
Mean POGO (SD) 16.4% (±14.3) 6.7% (±9.0) 11.8% (±5.6) 7.8% (±6.6)
p-Value 0.009 0.16
SD, standard deviation; GHD, growth hormone deficiency; ISS; idiopathic short stature; POGO, percentage of the gland occupied by the cyst.
Table 4: Prevalence of large versus small pituitary cysts in the 
different patient diagnoses.
Cyst patients GHD ISS
Small cysts 66.1% 55.6% 85.0%
p-Value 0.04
Large cysts 33.9% 44.4% 15.0%
p-Value 0.04
GHD, growth hormone deficiency; ISS; idiopathic short stature.
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gland, they are the most likely to be affected by a cyst [10, 
24, 25]. Given this relationship, one might hypothesize that 
children with poor growth may have a higher prevalence 
of cysts than the general pediatric population. However, in 
a recently completed study, we found a general pediatric 
population prevalence of cysts of 14.6%. This is greater than 
the 9.1% prevalence found in this study for short children. 
This tends to negate the hypothesis that cyst prevalence 
itself is related to poor growth and GHD. However, the dif-
ference in prevalence between our two studies is not com-
parable because higher resolution MRIs were utilized in 
the normal children study. Improved MRI technology may 
allow for more cysts of smaller size to be detected. The dif-
ference in cyst prevalence between GHD, ISS, and normal 
stature children warrants further investigation.
Cyst size may be a causative factor in cyst related pitu-
itary dysfunction. We found the mean cyst volume and 
POGO of cysts in GHD children to be significantly larger 
than in ISS children, implicating larger cysts with increas-
ing pituitary dysfunction. Furthermore, the volume and 
POGO of cysts in normal children [10] tended to be smaller 
than those of this study, with a mean volume and POGO of 
17.28 mm3 and 4.87%, respectively, in comparison to GHD 
(62 mm3, 15.3%) and ISS (29.4 mm3, 7.1%) patients.
Although cyst volume was greater in pubertal patients 
than prepubertal patients (p = 0.19), the difference in POGO 
between age groups was not significant (p = 0.46). This is 
likely because the pituitary size increases significantly in 
adolescence [26, 27]. If the POGO does not change, that is 
potentially indicative of only an increase in pituitary size, 
not an increase of cyst impingement on the gland.
From this data, we speculate that small cysts may 
be of a physiologic nature that come and go, but as cysts 
become larger, they may have a negative effect on pitui-
tary secretion and cause problems with normal growth, 
with the larger cysts causing GHD.
It should be noted that the difference in POGO was 
not significant between GHD and ISS females. This is 
likely due to a lower number of females in our study. As 
our study was retrospective, we were unable to account 
for pubertal stage. We acknowledge that careful Tanner 
staging is essential to future research. Additional research 
looking at pituitary cysts and GH production in children 
may include genetic analysis.
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